Skip to content

Study · Not a test of the peptide alone · 1987

3 results

Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.

Naylor PH, Naylor CW, Badamchian M, Wada S, Goldstein AL, Wang SS, Sun DK, Thornton AH, Sarin PS

Proceedings of the National Academy of Sciences of the United States of America1 May 1987Cited by 42 (Europe PMC)

PMID2437588 (opens in a new tab)PMCIDPMC304778 (opens in a new tab)DOI10.1073/pnas.84.9.2951 (opens in a new tab)PepBankPUB-02437588
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Mechanism

    In an HTLV-IIIB extract, HPLC and immunoblot analysis found a 17,000 molecular weight protein that is immunoreactive with thymosin alpha‑1.

    In plain wordsIn lab tests, a protein of the AIDS virus reacted with antibodies made against thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableHTLV-IIIB protein immunoreactive with thymosin alpha 1
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Infection

    Source sentences

    Summary
    Using HPLC and immunoblot analysis, we have identified from a clone B, type III human T-lymphotropic virus (HTLV-IIIB) extract a protein with a molecular weight of 17,000 that is immunoreactive with thymosin alpha 1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Mechanism

    No thymosin alpha‑1 immunoreactivity was found in retroviral extracts from feline, bovine, simian, gibbon and murine retroviruses.

    In plain wordsIn lab tests, retrovirus extracts from several animal species did not react with the thymosin alpha‑1 antibodies.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeThymosin alpha 1 immunoreactivity in non-human retroviral extracts
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Infection

    Source sentences

    Summary
    In contrast, no immunoreactivity was found in retroviral extracts from a number of nonhuman species including feline, bovine, simian, gibbon, and murine retroviruses.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Mechanism

    Antiserum against the synthetic peptide HGP-30 did not cross-react with thymosin alpha‑1 but did react with the p17 protein of the AIDS virus.

    In plain wordsIn lab tests, antibodies made against a 30-amino-acid virus peptide did not react with thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCross-reaction of HGP-30 antiserum with thymosin alpha 1
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Infection

    Source sentences

    Summary
    Heterologous antiserum prepared against a 30-amino acid synthetic peptide analogue (HGP-30) does not cross-react with thymosin alpha 1

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.